Statements (15)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:PTC_Therapeutics
|
| gptkbp:acquisitionYear |
2017
|
| gptkbp:controversy |
Emflaza pricing
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
rare diseases
|
| gptkbp:founded |
2008
|
| gptkbp:foundedBy |
gptkb:Jeffrey_Aronin
|
| gptkbp:headquarters_location |
gptkb:Northbrook,_Illinois
|
| https://www.w3.org/2000/01/rdf-schema#label |
Marathon Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Emflaza
|
| gptkbp:website |
www.marathonpharma.com
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|